Brief: Lexicon Pharmaceuticals And Novo Nordisk Announce Initiation Of Phase 1 Study With Oral Obesity Drug Candidate LX9851
23/03/2026 12:09
March 23 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O: LEXICON PHARMACEUTICALS AND NOVO NORDISK ANNOUNCE INITIATION OF PHASE 1 STUDY WITH ORAL OBESITY DRUG CANDIDATE LX9851 LEXICON PHARMACEUTICALS INC - EARNS SECOND $10 MILLION MILESTONE; ELIGIBLE FOR UP TO $1 BILLION IN PAYMENTS LEXICON PHARMACEUTICALS INC - PHASE 1 STUDY OF LX9851 EXPECTED TO COMPLETE IN Q1 2027 Source text: ID:nGNX37N8nH Further company coverage: LXRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexicon Pharmaceuticals
See all newsLexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Lexicon Pharmaceuticals posts Q2 net loss
Brief: Lexicon Pharmaceuticals Q2 EPS USD -0.07
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview